| Literature DB >> 35932321 |
Jonas Neubauer1, Konstantinos Gklavas2, Friederike Kortüm2, Mariya Gosheva2, Karl Ulrich Bartz-Schmidt2, Focke Ziemssen2,3.
Abstract
PURPOSE: To investigate whether compulsory face masking in public life changes the incidence or pattern of post-injection endophthalmitis (PIE). PATIENTS AND METHODS: All injections of bevacizumab, ranibizumab, aflibercept, dexamethasone or triamcinolone between 01/01/2015 and 12/31/2021 at the University Eye Clinic of Tuebingen were included in this retrospective analysis. The injection procedure itself was unchanged since 2015 and included the use of a sterile drape covering the head up to the shoulders which prevents airflow toward the eye. Furthermore, all staff wore a face mask and gloves at all times. The two study periods were defined by the introduction of a compulsory face masking rule in public life (01/01/2015 until 04/27/2020 vs. 04/28/2020 until 12/31/2021).Entities:
Keywords: Bacteria; Covid-19; Endophthalmitis; Face mask; Intravitreal injection; Post-injection endophthalmitis
Year: 2022 PMID: 35932321 PMCID: PMC9362425 DOI: 10.1007/s00417-022-05768-6
Source DB: PubMed Journal: Graefes Arch Clin Exp Ophthalmol ISSN: 0721-832X Impact factor: 3.535
Summary of documented intravitreal injections and registered post-injection-endophthalmitides (PIE)
| Pre-pandemic | Pandemic | ||
|---|---|---|---|
| Intravitreal injection | |||
| Bevacizumab | 4 (31%) | 4 (57%) | 0.24 |
| Aflibercept | 3 (23%) | 3 (43%) | 0.16 |
| Ranibizumab | 3 (23%) | - | - |
| Dexamethasone | - | - | - |
| Triamcinolone | 3 (23%) | - | - |
| Total injections | 62,044 | 21,499 | |
| PIE | 13 | 7 | 0.49 |
Summary of all PIE vitreous samples
| Patient ID | Causative injection | Pathogen | Gentamicin | Oxacillin | Cefazolin | Tetracyclin | Cotrimoxazole | Erythromycin | Clindamycin | Ciprofloxacin | Vancomycin | Rifampicin | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-pandemic | 1 | Ranibizumab | S. epidermidis | R | R | R | I | S | R | S | R | S | S |
| 2 | Triamcinolone | S. epidermidis | S | S | S | S | S | S | S | R | S | S | |
| 3 | Bevacizumab | S. epidermidis | S | S | S | I | I | R | R | R | S | S | |
| 4 | Ranibizumab | S. epidermidis | S | S | S | I | S | S | S | S | S | S | |
| 5 | Triamcinolone | S. epidermidis | S | S | S | S | R | S | S | S | S | S | |
| 6 | Aflibercept | S. epidermidis | S | S | S | I | S | R | S | S | S | S | |
| 7 | Bevacizumab | S. aureus | S | S | S | S | S | S | S | I | S | S | |
| 8 + 9 | Ranibizumab, Aflibercept | S. epidermidis * | N/A | ||||||||||
| 10–13 | Bevacizumab, Aflibercept, Bevacizumab, Triamcinolone | Unknown | |||||||||||
| Pandemic | 14 | Aflibercept | S. epidermidis | S | R | R | S | S | S | S | R | S | S |
| 15 | Aflibercept | S. epidermidis | S | N/A | R | R | S | R | N/A | I | S | S | |
| 16 | Aflibercept | S. lugdunensis | R | S | S | S | S | S | S | S | S | S | |
| 17 | Bevacizumab | S. aureus | S | S | S | S | S | S | S | S | S | S | |
| 18 | Bevacizumab | S. aureus | S | S | S | S | S | S | S | I | S | S | |
| 19 + 20 | Bevacizumab, Bevacizumab | Unknown | N/A | ||||||||||
S sensible, I inhibition, R resistant, S. Staphylococcus, N/A not available
*Detection of the bacterial strain via PCR